Table of Content
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ASHERMAN’S SYNDROME MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2. MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ASHERMAN’S SYNDROME MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ASHERMAN’S SYNDROME MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3. MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6. INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.1.1 PATENT LANDSCAPE
6.1.2 USPTO NUMBER
6.1.3 PATENT EXPIRY
6.1.4 EPIO NUMBER
6.1.5 PATENT STRENGTH AND QUALITY
6.1.6 PATENT CLAIMS
6.1.7 PATENT CITATIONS
6.1.8 PATENT LITIGATION AND LICENSING
6.1.9 FILE OF PATENT
6.1.10 PATENT RECEIVED CONTRIES
6.1.11 TECHNOLOGY BACKGROUND
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH SPECIALIST
6.8 OTHER KOL SNAPSHOTS
7. EPIDEMIOLOGY
7.1 INCIDENCE OF ALL BY GENDER
7.2 TREATMENT RATE
7.3 MORTALITY RATE
7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
7.5 PATIENT TREATMENT SUCCESS RATES
8. MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9. REGULATORY FRAMEWORK
9.1 REGULATORY APPROVAL PROCESS
9.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
9.3 REGULATORY APPROVAL PATHWAYS
9.4 LICENSING AND REGISTRATION
9.5 POST-MARKETING SURVEILLANCE
9.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
10. PIPELINE ANALYSIS
10.1 CLINICAL TRIALS AND PHASE ANALYSIS
10.2 DRUG THERAPY PIPELINE
10.3 PHASE III CANDIDATES
10.4 PHASE II CANDIDATES
10.5 PHASE I CANDIDATES
10.6 OTHERS (PRE-CLINICAL AND RESEARCH)
>11. MARKETED DRUG ANALYSIS
11.1 DRUG
11.1.1 BRAND NAME
11.1.2 GENERICS NAME
11.2 THERAPEUTIC INDICTION
11.3 PHARMACOLOGICAL CLASS OF THE DRUG
11.4 DRUG PRIMARY INDICATION
11.5 MARKET STATUS
11.6 MEDICATION TYPE
11.7 DRUG DOSAGES FORM
11.8 DOSAGES AVAILABILITY
11.9 DRUG ROUTE OF ADMINISTRATION
11.10 DOSING FREQUENCY
11.11 DRUG INSIGHT
11.12 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
11.12.1 FORECAST MARKET OUTLOOK
11.12.2 CROSS COMPETITION
11.12.3 THERAPEUTIC PORTFOLIO
11.12.4 CURRENT DEVELOPMENT SCENARIO
12. MARKET ACCESS
12.1 10-YEAR MARKET FORECAST
12.2 CLINICAL TRIAL RECENT UPDATES
12.3 ANNUAL NEW FDA APPROVED DRUGS
12.4 DRUGS MANUFACTURER AND DEALS
12.5 MAJOR DRUG UPTAKE
12.6 CURRENT TREATMENT PRACTICES
12.7 IMPACT OF UPCOMING THERAPY
13. R & D ANALYSIS
13.1 COMPARATIVE ANALYSIS
13.2 DRUG DEVELOPMENTAL LANDSCAPE
13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
13.4 THERAPEUTIC ASSESSMENT
13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
14. MARKET OVERVIEW
14.1 DRIVERS
14.2 RESTRAINTS
14.3 OPPORTUNITIES
14.4 CHALLENGES
15. GLOBAL ASHERMAN’S SYNDROME MARKET, BY TREATMENT
15.1 OVERVIEW
15.2 SURGERY
15.2.1 HYSTEROSCOPIC ADHESIOLYSIS
15.2.1.1. MECHANICAL
15.2.1.2. ELECTRICAL
15.2.1.3. THERMAL
15.2.2 LAPAROSCOPIC ADHESIOLYSIS
15.2.3 OTHERS
15.3 NON SURGICAL
15.3.1 PHARMACOLOGICAL THERAPY
15.3.1.1. ANTIBIOTIC
15.3.1.1.1. CIPROFLOXACIN
15.3.1.1.2. DOXYCYCLINE
15.3.1.1.3. CEFIXIME
15.3.1.1.4. OTHERS
15.3.1.2. ESTROGEN TABLETS
15.3.1.2.1. PREMARIN
15.3.1.2.2. PREMPRO
15.3.1.2.3. ACTIVELLA
15.3.1.2.4. OTHERS
15.3.1.3. BIRTH CONTROL PATCHES
15.3.1.4. OTHERS
15.3.2 PHYSICAL THERAPY
15.3.3 OTHERS
15.4 STEM CELLS TREATMENT
16. GLOBAL ASHERMAN’S SYNDROME MARKET, BY PRODUCT TYPE
16.1 OVERVIEW
16.2 INTRAUTERINE DEVICES (IUDS)
16.3 ANTI-ADHESION PRODUCTS
16.4 UTERINE BALLOON STENT
16.5 FOLEY'S CATHETER
16.6 HORMONAL THERAPY PRODUCTS
16.7 OTHERS
17. GLOBAL ASHERMAN’S SYNDROME MARKET, BY DIAGNOSIS
17.1 OVERVIEW
17.2 HYSTEROSALPINGOGRAPHY
17.3 TRANSVAGINAL ULTRASOUND
17.4 HYSTEROSONOGRAM
17.5 HYSTEROSCOPY
17.6 OTHERS
18. GLOBAL ASHERMAN’S SYNDROME MARKET, BY ROUTE OF ADMINISTRATION
18.1 OVERVIEW
18.2 ORAL
18.2.1 TABLET
18.2.2 PILLS/CAPSULES
18.2.3 OTHERS
18.3 PARENTERAL
18.3.1 INTRAVENOUS
18.3.2 TRANSDERMAL
18.3.3 OTHERS
18.4 OTHERS
19. GLOBAL ASHERMAN’S SYNDROME MARKET, BY DRUGS TYPE
19.1 OVERVIEW
19.2 BRANDED
19.3 GENERICS
20. GLOBAL ASHERMAN’S SYNDROME MARKET, BY POPULATION TYPE
20.1 OVERVIEW
20.2 PEDIATRIC
20.2.1 BY SEVERITY LEVEL
20.2.1.1. MILD
20.2.1.2. MODERATE
20.2.1.3. SEVERE
20.2.2 BY CHRONIC LEVEL
20.2.2.1. PRIMARY
20.2.2.2. SECONDARY
20.3 ADULTS
20.3.1 BY SEVERITY LEVEL
20.3.1.1. MILD
20.3.1.2. MODERATE
20.3.1.3. SEVERE
20.3.2 BY CHRONIC LEVEL
20.3.2.1. PRIMARY
20.3.2.2. SECONDARY
20.4 GERIATRIC
20.4.1 BY SEVERITY LEVEL
20.4.1.1. MILD
20.4.1.2. MODERATE
20.4.1.3. SEVERE
20.4.2 BY CHRONIC LEVEL
20.4.2.1. PRIMARY
20.4.2.2. SECONDARY
21. GLOBAL ASHERMAN’S SYNDROME MARKET, BY SEVERITY LEVEL
21.1 OVERVIEW
21.2 MILD
21.3 MODERATE
21.4 SEVERE
22. GLOBAL ASHERMAN’S SYNDROME MARKET, BY PRESCRIPTION TYPE
22.1 OVERVIEW
22.2 PRESCRIPTION DRUGS
22.3 OVER THE COUNTER
23. GLOBAL ASHERMAN’S SYNDROME MARKET, BY END USER
23.1 OVERVIEW
23.2 HOSPITAL
23.2.1 PRIVATE
23.2.2 GOVERNMENT
23.3 SPECIALTY CLINICS
23.4 HOME HEALTHCARE
23.5 AMBULATORY SURGICAL CENTER
23.6 OTHERS
24. GLOBAL ASHERMAN’S SYNDROME MARKET, BY DISTRIBUTION CHANNEL
24.1 OVERVIEW
24.2 DIRECT TENDER
24.3 RETAIL SALES
24.3.1 HOSPITAL PHARMACY
24.3.2 ONLINE PHARMACY
24.3.3 MEDICINE STORES
24.4 OTHERS
25. GLOBAL ASHERMAN’S SYNDROME MARKET, COMPANY LANDSCAPE
25.1 COMPANY SHARE ANALYSIS: GLOBAL
25.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
25.3 COMPANY SHARE ANALYSIS: EUROPE
25.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
25.5 MERGERS & ACQUISITIONS
25.6 NEW PRODUCT DEVELOPMENT & APPROVALS
25.7 EXPANSIONS
25.8 REGULATORY CHANGES
25.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
26. GLOBAL ASHERMAN’S SYNDROME MARKET, BY GEOGRAPHY
GLOBAL ASHERMAN’S SYNDROME MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
26.1 NORTH AMERICA
26.1.1 U.S.
26.1.2 CANADA
26.1.3 MEXICO
26.2 EUROPE
26.2.1 GERMANY
26.2.2 U.K.
26.2.3 ITALY
26.2.4 FRANCE
26.2.5 SPAIN
26.2.6 RUSSIA
26.2.7 SWITZERLAND
26.2.8 TURKEY
26.2.9 BELGIUM
26.2.10 NETHERLANDS
26.2.11 DENMARK
26.2.12 SWEDEN
26.2.13 POLAND
26.2.14 NORWAY
26.2.15 FINLAND
26.2.16 REST OF EUROPE
26.3 ASIA-PACIFIC
26.3.1 JAPAN
26.3.2 CHINA
26.3.3 SOUTH KOREA
26.3.4 INDIA
26.3.5 SINGAPORE
26.3.6 THAILAND
26.3.7 INDONESIA
26.3.8 MALAYSIA
26.3.9 PHILIPPINES
26.3.10 AUSTRALIA
26.3.11 NEW ZEALAND
26.3.12 VIETNAM
26.3.13 TAIWAN
26.3.14 REST OF ASIA-PACIFIC
26.4 SOUTH AMERICA
26.4.1 BRAZIL
26.4.2 ARGENTINA
26.4.3 REST OF SOUTH AMERICA
26.5 MIDDLE EAST AND AFRICA
26.5.1 SOUTH AFRICA
26.5.2 EGYPT
26.5.3 BAHRAIN
26.5.4 UNITED ARAB EMIRATES
26.5.5 KUWAIT
26.5.6 OMAN
26.5.7 QATAR
26.5.8 SAUDI ARABIA
26.5.9 REST OF MIDDLE EAST AND AFRICA
26.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
27. GLOBAL ASHERMAN’S SYNDROME MARKET, SWOT AND DBMR ANALYSIS
28. GLOBAL ASHERMAN’S SYNDROME MARKET, COMPANY PROFILE
28.1 IGENOMIX
28.1.1 COMPANY OVERVIEW
28.1.2 REVENUE ANALYSIS
28.1.3 GEOGRAPHIC PRESENCE
28.1.4 PRODUCT PORTFOLIO
28.1.5 RECENT DEVELOPMENTS
28.2 SUN PHARMACEUTICAL INDUSTRIES, INC.
28.2.1 COMPANY OVERVIEW
28.2.2 REVENUE ANALYSIS
28.2.3 GEOGRAPHIC PRESENCE
28.2.4 PRODUCT PORTFOLIO
28.2.5 RECENT DEVELOPMENTS
28.3 TEVA PHARMACEUTICALS USA, INC.
28.3.1 COMPANY OVERVIEW
28.3.2 REVENUE ANALYSIS
28.3.3 GEOGRAPHIC PRESENCE
28.3.4 PRODUCT PORTFOLIO
28.3.5 RECENT DEVELOPMENTS
28.4 LUPIN PHARMACEUTICALS, INC
28.4.1 COMPANY OVERVIEW
28.4.2 REVENUE ANALYSIS
28.4.3 GEOGRAPHIC PRESENCE
28.4.4 PRODUCT PORTFOLIO
28.4.5 RECENT DEVELOPMENTS
28.5 AUROBINDO PHARMA USA
28.5.1 COMPANY OVERVIEW
28.5.2 REVENUE ANALYSIS
28.5.3 GEOGRAPHIC PRESENCE
28.5.4 PRODUCT PORTFOLIO
28.5.5 RECENT DEVELOPMENTS
28.6 PARATEK PHARMACEUTICALS, INC.
28.6.1 COMPANY OVERVIEW
28.6.2 REVENUE ANALYSIS
28.6.3 GEOGRAPHIC PRESENCE
28.6.4 PRODUCT PORTFOLIO
28.6.5 RECENT DEVELOPMENTS
28.7 TETRAPHASE PHARMACEUTICALS, INC.
28.7.1 COMPANY OVERVIEW
28.7.2 REVENUE ANALYSIS
28.7.3 GEOGRAPHIC PRESENCE
28.7.4 PRODUCT PORTFOLIO
28.7.5 RECENT DEVELOPMENTS
28.8 BASILEA PHARMACEUTICA LTD, ALLSCHWIL
28.8.1 COMPANY OVERVIEW
28.8.2 REVENUE ANALYSIS
28.8.3 GEOGRAPHIC PRESENCE
28.8.4 PRODUCT PORTFOLIO
28.8.5 RECENT DEVELOPMENTS
28.9 MELINTA THERAPEUTICS LLC
28.9.1 COMPANY OVERVIEW
28.9.2 REVENUE ANALYSIS
28.9.3 GEOGRAPHIC PRESENCE
28.9.4 PRODUCT PORTFOLIO
28.9.5 RECENT DEVELOPMENTS
28.10 VIATRIS INC.
28.10.1 COMPANY OVERVIEW
28.10.2 REVENUE ANALYSIS
28.10.3 GEOGRAPHIC PRESENCE
28.10.4 PRODUCT PORTFOLIO
28.10.5 RECENT DEVELOPMENTS
28.11 HIKMA PHARMACEUTICALS PLC
28.11.1 COMPANY OVERVIEW
28.11.2 REVENUE ANALYSIS
28.11.3 GEOGRAPHIC PRESENCE
28.11.4 PRODUCT PORTFOLIO
28.11.5 RECENT DEVELOPMENTS
28.12 ADVACARE PHARMA
28.12.1 COMPANY OVERVIEW
28.12.2 REVENUE ANALYSIS
28.12.3 GEOGRAPHIC PRESENCE
28.12.4 PRODUCT PORTFOLIO
28.12.5 RECENT DEVELOPMENTS
28.13 WELLONA PHARMA
28.13.1 COMPANY OVERVIEW
28.13.2 REVENUE ANALYSIS
28.13.3 GEOGRAPHIC PRESENCE
28.13.4 PRODUCT PORTFOLIO
28.13.5 RECENT DEVELOPMENTS
28.14 BHUMI PHARMACEUTICALS
28.14.1 COMPANY OVERVIEW
28.14.2 REVENUE ANALYSIS
28.14.3 GEOGRAPHIC PRESENCE
28.14.4 PRODUCT PORTFOLIO
28.14.5 RECENT DEVELOPMENTS
28.15 ADEN HEALTHCARE
28.15.1 COMPANY OVERVIEW
28.15.2 REVENUE ANALYSIS
28.15.3 GEOGRAPHIC PRESENCE
28.15.4 PRODUCT PORTFOLIO
28.15.5 RECENT DEVELOPMENTS
28.16 JACKSON LABORATORIES PVT LTD
28.16.1 COMPANY OVERVIEW
28.16.2 REVENUE ANALYSIS
28.16.3 GEOGRAPHIC PRESENCE
28.16.4 PRODUCT PORTFOLIO
28.16.5 RECENT DEVELOPMENTS
28.17 ZOIC BIOTECH PRIVATE LIMITED
28.17.1 COMPANY OVERVIEW
28.17.2 REVENUE ANALYSIS
28.17.3 GEOGRAPHIC PRESENCE
28.17.4 PRODUCT PORTFOLIO
28.17.5 RECENT DEVELOPMENTS
28.18 F. HOFFMANN-LA ROCHE LTD
28.18.1 COMPANY OVERVIEW
28.18.2 REVENUE ANALYSIS
28.18.3 GEOGRAPHIC PRESENCE
28.18.4 PRODUCT PORTFOLIO
28.18.5 RECENT DEVELOPMENTS
28.19 ANI PHARMACEUTICALS, INC.
28.19.1 COMPANY OVERVIEW
28.19.2 REVENUE ANALYSIS
28.19.3 GEOGRAPHIC PRESENCE
28.19.4 PRODUCT PORTFOLIO
28.19.5 RECENT DEVELOPMENTS
28.20 PFIZER INC.
28.20.1 COMPANY OVERVIEW
28.20.2 REVENUE ANALYSIS
28.20.3 GEOGRAPHIC PRESENCE
28.20.4 PRODUCT PORTFOLIO
28.20.5 RECENT DEVELOPMENTS
28.21 SANOFI
28.21.1 COMPANY OVERVIEW
28.21.2 REVENUE ANALYSIS
28.21.3 GEOGRAPHIC PRESENCE
28.21.4 PRODUCT PORTFOLIO
28.21.5 RECENT DEVELOPMENTS
28.22 GSK PLC.
28.22.1 COMPANY OVERVIEW
28.22.2 REVENUE ANALYSIS
28.22.3 GEOGRAPHIC PRESENCE
28.22.4 PRODUCT PORTFOLIO
28.22.5 RECENT DEVELOPMENTS
28.23 NOVARTIS AG
28.23.1 COMPANY OVERVIEW
28.23.2 REVENUE ANALYSIS
28.23.3 GEOGRAPHIC PRESENCE
28.23.4 PRODUCT PORTFOLIO
28.23.5 RECENT DEVELOPMENTS
28.24 DELMONT IMAGING
28.24.1 COMPANY OVERVIEW
28.24.2 REVENUE ANALYSIS
28.24.3 GEOGRAPHIC PRESENCE
28.24.4 PRODUCT PORTFOLIO
28.24.5 RECENT DEVELOPMENTS
28.25 STERIMED GROUP
28.25.1 COMPANY OVERVIEW
28.25.2 REVENUE ANALYSIS
28.25.3 GEOGRAPHIC PRESENCE
28.25.4 PRODUCT PORTFOLIO
28.25.5 RECENT DEVELOPMENTS
28.26 SCW MEDICATH LTD
28.26.1 COMPANY OVERVIEW
28.26.2 REVENUE ANALYSIS
28.26.3 GEOGRAPHIC PRESENCE
28.26.4 PRODUCT PORTFOLIO
28.26.5 RECENT DEVELOPMENTS
28.27 ABBOTT
28.27.1 COMPANY OVERVIEW
28.27.2 REVENUE ANALYSIS
28.27.3 GEOGRAPHIC PRESENCE
28.27.4 PRODUCT PORTFOLIO
28.27.5 RECENT DEVELOPMENTS
28.28 ABBVIE INC.
28.28.1 COMPANY OVERVIEW
28.28.2 REVENUE ANALYSIS
28.28.3 GEOGRAPHIC PRESENCE
28.28.4 PRODUCT PORTFOLIO
28.28.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
29. RELATED REPORTS
30. CONCLUSION
31. QUESTIONNAIRE
32. ABOUT DATA BRIDGE MARKET RESEARCH
